News summary

Moderna mRNA vaccine almost halves the risk of skin cancer returning

Source: Nature - Main • Published: 23 Oct 2026, 00:00

Summarized by Masters of Longevity from Nature - Main.

A phase III trial found intismeran with pembrolizumab reduced melanoma recurrence or death by 42%.

Moderna mRNA vaccine almost halves the risk of skin cancer returning
Key Takeaways
  • The trial enrolled 1,137 people with stage IIIB–IV melanoma.
  • Individual vaccines were designed by sequencing each patient's tumour.
  • The overall survival outcomes remain uncertain pending longer follow-up.
Read the full article at Nature - Main ↗

Continue exploring

Recommended MoL Picks

MoL PickCreatine and Cancer: Why New Mouse Studies Point in Opposite DirectionsCreatine strengthened antitumour immune cells in one mouse study—and promoted metastasis through platelets in another. The apparent contradiction reveals why neither result is a supplement recommendation.MoL PickBiotin for Hair Growth: The Weak Evidence—and the Blood-Test Risk Most People MissBiotin deficiency can affect hair. That does not mean more biotin makes healthy hair grow—and high doses can distort important laboratory results.MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.